Möchten Sie immer auf dem neuesten Stand bleiben?

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced...

New York, June 01, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced its 2026 MDA Engage Symposium series, bringing free, in-person educational and community-building...

New York, March 30, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates today’s announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA...

Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees...

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene...

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen...

New York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve),...

New York, Nov. 20, 2025 (GLOBE NEWSWIRE) -- This NFL season, during games in Weeks 12 and 13, hundreds of NFL players will step onto the field in custom-designed cleats as part of the 10th annual My...